Company’s 36-month beta value is 1.25.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATOS is 125.25M, and currently, short sellers hold a 9.86% ratio of that floaft. The average trading volume of ATOS on May 08, 2024 was 1.80M shares.
ATOS) stock’s latest price update
Atossa Therapeutics Inc (NASDAQ: ATOS)’s stock price has increased by 2.65 compared to its previous closing price of 1.70. However, the company has seen a 14.05% increase in its stock price over the last five trading sessions. Proactive Investors reported 2024-05-07 that Atossa Therapeutics Inc (NASDAQ:ATOS) has welcomed new guidelines released by the US Preventative Services Task Force that recommend women begin breast cancer screening starting at age 40. The biopharmaceutical company targeting breast cancer with its lead asset (Z)-endoxifen highlighted that the change to the recommended age comes in response to rising breast cancer rates among younger women and racial disparities in breast cancer diagnosis and mortality.
ATOS’s Market Performance
Atossa Therapeutics Inc (ATOS) has seen a 14.05% rise in stock performance for the week, with a -5.16% decline in the past month and a 84.21% surge in the past quarter. The volatility ratio for the week is 6.88%, and the volatility levels for the past 30 days are at 9.14% for ATOS. The simple moving average for the last 20 days is 11.86% for ATOS stock, with a simple moving average of 75.13% for the last 200 days.
Analysts’ Opinion of ATOS
Many brokerage firms have already submitted their reports for ATOS stocks, with Maxim Group repeating the rating for ATOS by listing it as a “Buy.” The predicted price for ATOS in the upcoming period, according to Maxim Group is $2 based on the research report published on January 26, 2018 of the previous year 2018.
ATOS Trading at 15.70% from the 50-Day Moving Average
After a stumble in the market that brought ATOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.46% of loss for the given period.
Volatility was left at 9.14%, however, over the last 30 days, the volatility rate increased by 6.88%, as shares sank -1.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +67.97% upper at present.
During the last 5 trading sessions, ATOS rose by +13.08%, which changed the moving average for the period of 200-days by +58.72% in comparison to the 20-day moving average, which settled at $1.5590. In addition, Atossa Therapeutics Inc saw 98.30% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATOS starting from Finn Jonathan, who purchase 25,000 shares at the price of $1.77 back on Apr 10 ’24. After this action, Finn Jonathan now owns 25,000 shares of Atossa Therapeutics Inc, valued at $44,250 using the latest closing price.
WEAVER GREGORY L, the Former EVP, CFO, & Director of Atossa Therapeutics Inc, sale 50,000 shares at $0.65 during a trade that took place back on Nov 15 ’23, which means that WEAVER GREGORY L is holding 55 shares at $32,500 based on the most recent closing price.
Stock Fundamentals for ATOS
The total capital return value is set at -0.34. Equity return is now at value -28.80, with -27.38 for asset returns.
Currently, EBITDA for the company is -31.35 million with net debt to EBITDA at 3.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.61.
Conclusion
In a nutshell, Atossa Therapeutics Inc (ATOS) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
